AR074435A1 - Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. - Google Patents
Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.Info
- Publication number
- AR074435A1 AR074435A1 ARP090104620A ARP090104620A AR074435A1 AR 074435 A1 AR074435 A1 AR 074435A1 AR P090104620 A ARP090104620 A AR P090104620A AR P090104620 A ARP090104620 A AR P090104620A AR 074435 A1 AR074435 A1 AR 074435A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally
- group
- substituent
- nr3co
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008307581 | 2008-12-02 | ||
| JP2009125256 | 2009-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074435A1 true AR074435A1 (es) | 2011-01-19 |
Family
ID=42026212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104620A AR074435A1 (es) | 2008-12-02 | 2009-12-01 | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. |
Country Status (40)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001626A1 (es) * | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| EP2181987B9 (en) * | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| WO2009136663A1 (en) * | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
| US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
| CA2868954A1 (en) * | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| ES2877570T3 (es) | 2012-08-22 | 2021-11-17 | Univ Cornell | Métodos para inhibir fascina |
| EA029412B1 (ru) | 2013-06-28 | 2018-03-30 | Бейджин, Лтд. | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf |
| EP3013797B1 (en) | 2013-06-28 | 2018-01-03 | BeiGene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| CN103382190B (zh) * | 2013-07-16 | 2015-01-14 | 浙江医药高等专科学校 | 一类噻唑并环己烷类化合物、其制备方法和用途 |
| CN103435572B (zh) * | 2013-07-16 | 2015-02-04 | 浙江医药高等专科学校 | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 |
| CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
| CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
| US9573946B2 (en) | 2014-02-20 | 2017-02-21 | Novita Pharmaceuticals, Inc. | Compounds and methods for inhibiting fascin |
| EP3169815B1 (en) | 2014-07-15 | 2020-12-23 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
| CN107405348B (zh) * | 2014-12-23 | 2021-06-11 | 点疗法-1公司 | Raf抑制剂与紫杉烷的组合 |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017165742A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments |
| WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| CN109053630B (zh) * | 2018-08-22 | 2022-04-01 | 中国人民解放军第二军医大学 | 一种苯并噻唑类衍生物及其用途 |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| TWI849043B (zh) | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| WO2020232445A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Modulators of pyrimidine nucleotide biosynthetic pathways |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CN112094248B (zh) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | 一种取代苯并噻唑类化合物及其用途 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CN115724837B (zh) * | 2022-10-26 | 2024-07-23 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的苯并噻唑衍生物及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2399026A (en) * | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
| US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| HUP0004024A3 (en) | 1997-09-26 | 2001-10-29 | Zentaris Gmbh | Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| PT1140840E (pt) * | 1999-01-13 | 2006-05-31 | Bayer Pharmaceuticals Corp | Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| ATE356117T1 (de) * | 1999-01-22 | 2007-03-15 | Kirin Brewery | Derivate des n-((chinolinyl)oxy)-phenyl)- harnstoffs und des n-((chinazolinyl)oxy)-phenyl)- harnstoffs mit antitumor aktivität |
| BR0012046A (pt) * | 1999-07-01 | 2002-05-14 | Ajinomoto Kk | Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| JP3663382B2 (ja) | 2000-02-15 | 2005-06-22 | スージェン・インコーポレーテッド | ピロール置換２−インドリノン蛋白質キナーゼ阻害剤 |
| GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
| ATE266022T1 (de) | 2000-03-06 | 2004-05-15 | Smithkline Beecham Plc | Imidazol derivate als raf kinase inhibitoren |
| AU2001281817B2 (en) | 2000-06-21 | 2005-11-24 | F. Hoffmann-La Roche Ag | Benzothiazole derivatives |
| US7199137B2 (en) | 2000-09-21 | 2007-04-03 | Smithkline Beecham Plc | Imidazole derivatives as Raf kinase inhibitors |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| JP2004517080A (ja) * | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| US7375105B2 (en) | 2001-09-05 | 2008-05-20 | Smithkline Beecham P.L.C. | Pyridine substituted furan derivatives as Raf kinase inhibitors |
| GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| US20040192689A1 (en) | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
| GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
| AU2003220970A1 (en) | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| WO2003082272A1 (en) | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
| WO2004087153A2 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| US7378233B2 (en) * | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
| DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
| DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| KR20060118472A (ko) | 2003-10-16 | 2006-11-23 | 카이론 코포레이션 | 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용 |
| WO2005112932A2 (en) | 2004-05-07 | 2005-12-01 | Exelixis, Inc. | Raf modulators and methods of use |
| MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR20060079098A (ko) | 2004-12-31 | 2006-07-05 | 주식회사 엘지생명과학 | 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체 |
| WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
| WO2006081172A2 (en) * | 2005-01-26 | 2006-08-03 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP4033409B1 (ja) | 2005-07-11 | 2008-01-16 | 田辺三菱製薬株式会社 | オキシム誘導体及びその製法 |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| WO2007058482A1 (en) | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
| CA2649288C (en) | 2006-04-19 | 2015-11-24 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| AU2007279595A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
| JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
| WO2008125633A2 (en) | 2007-04-13 | 2008-10-23 | Rikshospitalet - Radiumhospitalet Hf | Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
| EP2162552A4 (en) | 2007-05-11 | 2010-06-30 | Univ Johns Hopkins | BIOMARKER FOR MELANOME |
| BRPI0811097A2 (pt) | 2007-05-23 | 2014-12-09 | Novartis Ag | Inibidores de raf para o tratamento de câncer de tireoide |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| JP2008307581A (ja) | 2007-06-15 | 2008-12-25 | Sanyo Special Steel Co Ltd | 管材の洗浄装置 |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| JP5350247B2 (ja) | 2007-08-29 | 2013-11-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| JP2009125256A (ja) | 2007-11-22 | 2009-06-11 | Kandado:Kk | 安眠枕 |
| CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
| WO2009099991A2 (en) | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US20090275546A1 (en) * | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
| WO2009136663A1 (en) | 2008-05-08 | 2009-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2009
- 2009-11-25 JO JOP/2009/0448A patent/JO3101B1/ar active
- 2009-12-01 US US12/628,697 patent/US8143258B2/en not_active Expired - Fee Related
- 2009-12-01 HR HRP20151370TT patent/HRP20151370T1/hr unknown
- 2009-12-01 CN CN200980155786.1A patent/CN102300854B/zh not_active Expired - Fee Related
- 2009-12-01 EA EA201170735A patent/EA019447B1/ru not_active IP Right Cessation
- 2009-12-01 JP JP2011538209A patent/JP5640014B2/ja not_active Expired - Fee Related
- 2009-12-01 HU HUE09775337A patent/HUE026491T4/en unknown
- 2009-12-01 MY MYPI20112494 patent/MY150989A/en unknown
- 2009-12-01 RS RS20150768A patent/RS54370B9/sr unknown
- 2009-12-01 SI SI200931334T patent/SI2358689T1/sl unknown
- 2009-12-01 PL PL09775337T patent/PL2358689T3/pl unknown
- 2009-12-01 CA CA2745144A patent/CA2745144C/en active Active
- 2009-12-01 UY UY0001032281A patent/UY32281A/es not_active Application Discontinuation
- 2009-12-01 PE PE2011001128A patent/PE20110588A1/es active IP Right Grant
- 2009-12-01 PT PT97753370T patent/PT2358689E/pt unknown
- 2009-12-01 TW TW098140940A patent/TWI436987B/zh not_active IP Right Cessation
- 2009-12-01 AR ARP090104620A patent/AR074435A1/es active IP Right Grant
- 2009-12-01 EP EP09775337.0A patent/EP2358689B9/en active Active
- 2009-12-01 WO PCT/JP2009/070447 patent/WO2010064722A1/en not_active Ceased
- 2009-12-01 GE GEAP200912278A patent/GEP20146003B/en unknown
- 2009-12-01 ME MEP-2016-203A patent/ME02331B/me unknown
- 2009-12-01 MX MX2011005836A patent/MX2011005836A/es active IP Right Grant
- 2009-12-01 DK DK09775337.0T patent/DK2358689T5/en active
- 2009-12-01 SG SG2011038247A patent/SG171426A1/en unknown
- 2009-12-01 KR KR1020117015343A patent/KR101639092B1/ko not_active Expired - Fee Related
- 2009-12-01 AU AU2009323274A patent/AU2009323274B2/en not_active Ceased
- 2009-12-01 ES ES09775337.0T patent/ES2557304T3/es active Active
- 2009-12-01 NZ NZ593759A patent/NZ593759A/en not_active IP Right Cessation
- 2009-12-01 BR BRPI0922109-3A patent/BRPI0922109A2/pt not_active IP Right Cessation
-
2011
- 2011-05-26 IL IL213184A patent/IL213184A0/en active IP Right Grant
- 2011-05-30 TN TN2011000280A patent/TN2011000280A1/fr unknown
- 2011-06-01 CL CL2011001299A patent/CL2011001299A1/es unknown
- 2011-06-01 DO DO2011000165A patent/DOP2011000165A/es unknown
- 2011-06-23 ZA ZA2011/04659A patent/ZA201104659B/en unknown
- 2011-06-24 CR CR20110366A patent/CR20110366A/es unknown
- 2011-06-29 EC EC2011011165A patent/ECSP11011165A/es unknown
- 2011-06-30 CO CO11082152A patent/CO6400140A2/es active IP Right Grant
- 2011-06-30 MA MA33985A patent/MA32911B1/fr unknown
-
2012
- 2012-01-10 US US13/347,302 patent/US8497274B2/en not_active Expired - Fee Related
-
2015
- 2015-12-15 SM SM201500316T patent/SMT201500316B/it unknown
- 2015-12-17 CY CY20151101155T patent/CY1117178T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| BR112015023397A2 (pt) | benzoxazois substituídos e métodos de uso dos mesmos | |
| GT200400092A (es) | Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| BRPI0605921B8 (pt) | compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| UY28693A1 (es) | Compuestos utiles en terapia | |
| NI201000011A (es) | Derivados de pirimidina 934. | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| CY1116120T1 (el) | Παραγωγα ιμιδαζοπυριδινης ή ιμιδαζοπυριμιδινης ως αναστολεις φωσφοδιεστερασης 10α | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| PE20141352A1 (es) | Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |